查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
瀰漫性大 B 細胞淋巴瘤治療的全球市場 - 2022-2029
市場調查報告書
商品編碼
1146456

瀰漫性大 B 細胞淋巴瘤治療的全球市場 - 2022-2029

Global Diffuse Large B-cell Lymphoma Therapeutics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

預計 2021 年全球瀰漫性大 B 細胞淋巴瘤治療市場價值 41.075 億美元，在預測期內（2022-2029 年）以 7.50% 的複合年增長率增長。

瀰漫性大 B 細胞淋巴瘤 (DLBCL) 是最常見的非霍奇金淋巴瘤 (NHL) 類型。DLBCL 是一種影響 B 淋巴細胞的侵襲性（快速增殖）NHL。淋巴細胞是一種白細胞。B 細胞是產生抗體以抵抗感染的淋巴細胞，是淋巴系統的重要組成部分。

市場動態

全球瀰漫性大 B 細胞淋巴瘤治療市場的增長是由 DLBCL（瀰漫性大 B 細胞淋巴瘤）發病率的增加、對靶向治療的日益偏好以及技術與先進藥物療法相結合所帶來的進步所推動的。

對靶向治療的日益偏好預計將在預測期內推動增長

靶向治療是最廣泛提倡的瀰漫性大 B 細胞淋巴瘤治療方法之一，因為它對健康細胞的毒性低於化學療法。靶向治療作用於與癌症相關的特定分子靶點。用於 NHL 的靶向治療包括單克隆抗體、激□抑製劑、免疫調節劑和核輸出抑製劑。利妥昔單抗是一種靶向治療藥物，用於治療各種類型的 B 細胞非霍奇金淋巴瘤。它通過靶向一種稱為 CD20 的分子起作用，該分子存在於正常 B 細胞和 B 細胞非霍奇金淋巴瘤的細胞表面。Ibrutinib 是一種靶向療法，可抑制 Bruton 酪氨酸激□通路。套細胞淋巴瘤、邊緣區淋巴瘤、小淋巴細胞淋巴瘤和 B 細胞淋巴瘤如慢性淋巴細胞白血病和華氏巨球蛋白血症已獲批准。

分子生物學的最新進展提高了我們對 DLBCL 致癌物的理解，並導致了許多靶向治療的發展，目前正在 I 期和 II 期試驗中進行評估。Ibrutinib (Imbruvica) 是一種經 FDA 批准用於多種類型淋巴瘤的靶向療法，目前正在 DLBCL 中進行測試，以查看它是否會以不同方式影響亞型。

高昂的處理成本可能會阻礙市場增長

治療瀰漫性大 B 細胞淋巴瘤的高成本預計將限制接受治療的個體數量，在一定程度上抑制市場增長。治療瀰漫性大 B 細胞淋巴瘤 (RR DLBCL) 的費用可能非常昂貴，而且僅當考慮一線和二線治療費用高達 200,000 美元時。在國際藥物經濟學和結果研究學會年度國際會議上發表的一項研究估計了三線治療的終生直接醫療費用和該疾病的後續治療費用。作者通過將治療的平均售價加上 2017 年提供者的直接成本來計算三線治療的成本。考慮的其他成本包括不良事件、治療管理和監測、疾病管理以及未來的醫療保健成本。

終生成本從 600,000 美元到 750,000 美元不等，與三線治療相關的不良事件佔總成本的 30%。據信其他費用包括獲得治療 (28%) 和後續治療 (21%)。RR DLBCL 的終生治療費用接近並可能超過 100 萬美元，包括一線和二線治療的費用。

COVID-19的影響分析

COVID-19 大流行繼續危害全球健康並阻礙全球經濟。廣泛觀察到，先前存在瀰漫性大 B 細胞淋巴瘤的患者因 COVID-19 而出現更高的並發症。

正在進行的化療對 COVID-19 患者預後的影響程度仍有爭議，但至少一項大型研究發現，在診斷為 COVID-19 時接受治療的瀰漫性大 B 細胞淋巴瘤患者發生嚴重並發症的風險增加.還有數據表明，淋巴瘤患者更容易感染 SARS-CoV-2。根據一份報告，在感染 COVID-19 的患者中，治療強度越大，對臨床結果的影響就越大。據報導，血液系統惡性腫瘤患者的發病率和死亡率都很高，這凸顯了這一患者群體的脆弱性。

大多數中心在患者開始治療時、按月或在他們入院接受治療時在門診對患者進行篩查。實施將根據 COVID-19 的流行程度和是否進行篩查而有所不同。陽性時的治療時機和治療方法需要個別判斷。發表在 Blood Advances 上的一項研究發現，正在積極接受抗 CD20 抗體治療的瀰漫性大 B 細胞淋巴瘤患者對 BNT162b2 mRNA（Pfizer Biointech, Inc.）COVID-19 疫苗的反應更好。顯示正在下降。接受過抗 CD20 治療的患者對 COVID-19 疫苗的反應可能會降低。絕對淋巴細胞計數高的患者也不太可能對疫苗產生反應。對於目前正在接受治療的患者來說，這將是一個問題。

細分分析

免疫學和靶向治療領域預計將在該細分市場中佔據最大份額

靶向治療是一種在不影響正常細胞的情況下，通過藥物精準“靶向”癌細胞的癌症治療方法。靶向療法是有效的治療方法，但許多人更喜歡將它們與其他療法結合使用，例如常規或標準化療、手術或放射療法。研究和開發致癌的 DNA 改變和蛋白質已證明可用於設計針對此類蛋白質的有前途的療法。不同類型的癌症有針對每種癌症的不同類型的藥物。但是測試腫瘤可以確認目標，如果有藥物，可以治療它。由於傳統化學療法可以在傷害正常細胞的同時殺死癌細胞，因此預計靶向治療領域將在預測期內增長。由於瀰漫性大 B 細胞淋巴瘤 (DLBCL) 的發病率不斷增加，靶向癌症治療市場正在擴大。例如，瀰漫性大 B 細胞淋巴瘤 (DLBCL) 是美國最常見的非霍奇金淋巴瘤 (NHL) 類型，約占美國新診斷 B 細胞 NHL 病例的 22%，根據到淋巴瘤協會。佔領。每年有超過 18,000 人被診斷出患有 DLBCL。

為 DLBCL 開發新藥和治療方法的研發工作十分活躍。來自不同公司的多種產品正處於不同的臨床試驗階段，預計將在預測期內進入市場。例如，Roche的 Glofitamab（抗 CD20 CD3 TCB，RG6026）是一種結合 T 細胞的雙特異性抗體，旨在結合 B 細胞上的 CD20 和 T 細胞上的 CD3。通過同時作用於 B 細胞上的 CD20 和 T 細胞上的 CD3，可以通過激活 T 細胞並攻擊和消除 B 細胞來治療非霍奇金淋巴瘤等 B 細胞癌。

區域分析

北美佔全球瀰漫性大 B 細胞淋巴瘤市場的最大市場份額。

由於瀰漫性大 B 細胞淋巴瘤 (DLBCL) 患者數量增加和公眾醫療保健意識提高等因素，北美佔據了市場主導地位。瀰漫性大 B 細胞淋巴瘤 (DLBCL) 是美國最常見的非霍奇金淋巴瘤 (NHL) 類型，約占美國新診斷 B 細胞 NHL 病例的 22 例，根據淋巴瘤社區.%.每年有超過 18,000 人被診斷出患有 DLBCL。該地區的 DLBCL 發病率以及非霍奇金淋巴瘤 (NHL) 發病率呈上升趨勢，再加上潛在的人口變化，預計估計會增加。DLBCL 是一種成熟的 B 細胞腫瘤，由生髮中心和生髮後中心 B 細胞發展而來。

此外，越來越多的製造商正專注於採用合作和收購等無機增長戰略，以加強其在復發/難治性瀰漫性大 B 細胞淋巴瘤領域的產品組合，這正在推動該地區的市場，有望促進增長。例如，FDA 最近批准了 Monjuvi (tafasitamab-cxix) 與來那度胺聯合用於治療復發或難治性瀰漫性大 B 細胞淋巴瘤 (DLBCL) 成年患者。

競爭格局

全球瀰漫性大 B 細胞淋巴瘤治療市場競爭激烈，既有本地參與者也有全球參與者。為市場增長做出貢獻的主要參與者包括 F. Hoffmann-La Roche Ltd、Novartis AG、Celltrion、Karyopharm Therapeutics、Kite Pharma、MorphoSys AG、AbbVie、CTI BioPharma、Seagen Inc.、TG Therapeutics 等增長。領先的公司正在採用多種增長戰略，例如產品發布、收購和合作夥伴關係，這有助於傷口護理管理設備領域的發展。例如，2019 年 2 月 19 日，FDA 批准了 polatozumab 治療復發或難治性 (R/R) 瀰漫性大 B 細胞淋巴瘤 (DLBCL) 患者，我們已授予 vedotin 優先審評權。

全球瀰漫性大 B 細胞淋巴瘤治療市場——值得關注的主要參與者

F. Hoffmann La Roche

公司概況 Roche於 1896 年在瑞士巴塞爾成立。我們開發創新藥物和診斷測試，幫助全球數百萬患者。Roche是最早為患者提供靶向治療的公司之一。結合製藥和診斷方面的優勢，羅氏比任何其他公司都更有能力進一步推進個性化醫療保健。三分之二的研發項目與伴隨診斷有關。基因泰克於 2009 年 3 月成為羅氏集團的一部分。Roche是日本Chugai Pharmaceutical的大股東。

Product Portfolio 產品組合：Rituxan (Rituximab)/MabThera 是第一種治療性單克隆抗體，靶向細胞表面帶有 CD20 標記的細胞。這些細胞是許多血癌的核心，包括常見的淋巴瘤和白血病。

重大發展。2019 年 6 月，美國 FDA 批准Roche的多病毒療法聯合苯達莫司汀加利妥昔單抗（rituximab）用於既往接受過治療的侵襲性淋巴瘤、瀰漫性大 B 細胞淋巴瘤 (DLBCL) 患者。獲批 (BR)。

目錄

第一章 調查方法和範圍

  • 調查方法
  • 調查目的和範圍

第二章市場定義和概述

第三章執行摘要

  • 按藥物類型劃分的市場細分
  • 按給藥途徑劃分的市場細分
  • 最終用戶的市場細分
  • 區域市場細分

第四章市場動態

  • 市場影響因素
    • 促進者
      • 越來越偏愛靶向治療
    • 抑製劑
      • 飆升的治療費用
    • 市場機會
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 專利分析
  • 管道分析
  • 流行病學
  • 供應鏈分析
  • 定價分析
  • 法律法規分析
  • 未滿足的需求

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 中的價格動態
  • 供需譜
  • 大流行期間與市場相關的政府努力
  • 製造商的戰略舉措
  • 概括

第 7 章 按藥物類型

  • 免疫學/靶向藥物
    • 利妥昔單抗（Rituxan）
    • polatuzumab vedotin 峰 (Polivy)
    • Tisagenlecleucel（Kymriah）（英文名：Kymriah）
    • tafasitamab-cxix (monjuvi)
    • Selinexar（XPOVIO）
    • Axicabutadiene siroleucer (Yescarta)
    • 其他（派姆單抗（Keytruda）、依魯替尼）
  • 其他 - 合併用藥

第八章 行政途徑

  • 靜脈給藥途徑
    • 口服給藥

第 9 章最終用戶

  • 醫院
  • 癌症中心
  • 其他

第10章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 亞太其他地區
  • 中東/非洲

第 11 章 競爭格局

  • 主要發展和戰略
  • 公司股份分析
  • 產品基準
  • 值得關注的主要公司
  • 具有顛覆性技術的公司
  • 初創公司

第十二章公司簡介

  • F. Hoffmann-La Roche Ltd
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Novartis AG
  • Celltrion
  • Karyopharm Therapeutics
  • Kite Pharma
  • MorphoSys AG
  • AbbVie
  • CTI BioPharma
  • Seagen Inc
  • TG Therapeutics

第 13 章瀰漫性大 B 細胞淋巴瘤藥物的全球市場-DataM

簡介目錄
Product Code: DMPH1271

Market Overview

The global diffuse large b-cell lymphoma therapeutics market size was worth US$ 4,107.50 million in 2021 and is growing at a CAGR of 7.50 % during the forecast period (2022-2029).

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL). DLBCL is an aggressive (fast-growing) NHL that affects B-lymphocytes. Lymphocytes are one type of white blood cell. B-cells are lymphocytes that make antibodies to fight infections and are an important part of the lymphatic system.

Market Dynamics

The global diffuse large b-cell lymphoma therapeutics market growth is driven by the increasing incidence of DLBCL (Diffuse Large B-Cell Lymphoma), increasing preference for targeted therapies and technological advancement coupled with advanced drug therapeutics.

Increasing preference for targeted therapies is expected to drive the growth in the forecast period

Targeted therapy is one of the most widely preferred methods for the treatment of diffuse large B-cell lymphoma, as targeted therapy is less toxic to healthy cells than chemotherapy. Targeted therapies act on specific molecular targets that are associated with cancer. Monoclonal antibodies, kinase inhibitors, immunomodulatory drugs, and nuclear export inhibitors are among the targeted therapies used for NHL. Rituximab is a targeted therapy that is used to treat a variety of B-cell NHL types. It works by focusing on a molecule known as CD20, which is found on the surface of both normal B cells and B-cell NHL cells. Ibrutinib is a targeted therapy that inhibits the Bruton's tyrosine kinase pathway. Mantle cell lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma, as well as chronic lymphocytic leukaemia and Waldenstrom macroglobulinemia, are among the B-cell lymphomas for which it has been approved.

Recent progress in molecular biology has led to a better understanding of the oncogenic drivers of DLBCL, resulting in the development of a large number of targeted therapies undergoing evaluation in phase I and II trials. Ibrutinib (Imbruvica), a targeted therapy approved by the FDA for use in multiple forms of lymphoma, has been tested in DLBCL to investigate if it affects the subtypes differently.

High cost of treatment is likely to hamper the market growth

The high cost associated with the treatment of diffuse large B-cell lymphoma is expected to restrain the market growth to a certain extent, as this limits the number of individuals undergoing the treatment. The cost to treat diffuse large B-cell lymphoma (RR DLBCL) can be high-and that's only taking into account first- and second-line treatments that can cost as much as $200,000. A study presented at the International Society of Pharmacoeconomics and Outcomes Research Annual International Meeting estimated the lifetime direct medical costs of third-line and subsequent treatment costs for this disease. The authors calculated the cost of third-line therapies by adding the Average Sales Price of therapies, plus the direct costs to providers in 2017. Some of the other costs considered were adverse events, treatment administration and monitoring, disease management, and future healthcare costs

They discovered that lifetime costs can vary from $600,000 to $750,000, with the costs of adverse events related to third-line treatment representing 30% of the total cost. Treatment acquisition (28%) and subsequent therapy (21%) are the other costs considered included. The lifetime cost of treating RR DLBCL can approach and surpass $1 million after including the costs of first- and second-line therapies.

COVID-19 Impact Analysis

The COVID-19 pandemic continues to endanger global health and hinder the world economy; It has been widely observed that patients with existing diffuse large b-cell lymphoma experience higher complications due to COVID-19.

The degree to which ongoing chemotherapy impacts the outcome of patients with COVID-19 remains controversial, but at least one large study shows that individuals with diffuse large b-cell lymphoma undergoing treatment when diagnosed with COVID-19 are at high risk of severe complications. There are also data suggesting that patients with lymphoma have an increased susceptibility to infection with SARS-CoV-2. According to one report, the more intense the therapy, the greater the impact on clinical outcomes in patients who contract COVID-19. The high morbidity and mortality rates reported in patients with hematologic malignancies underscore the vulnerability of this patient population.

Most centers are screening patients beginning therapy in the out-patient clinic or even monthly on an on-going basis, or on admission to the hospital for treatment. Practices differ depending on the prevalence of COVID-19 and the availability of screening. The decision on when and how to treat in the face of a positive result must be individualized. Patients with diffuse large b-cell lymphoma who are actively undergoing treatment with an anti-CD20 antibody have an impaired response to the BNT162b2 mRNA (by Pfizer-BioNTech) COVID-19 vaccine, according to research published in Blood Advances. Patients who had any exposure to anti-CD20 therapy were less likely to have a response to the COVID-19 vaccine. Patients with an absolute lymphocyte count were also less likely to respond to the vaccine. This will create problem for patients who are presently taking therapies.

Segment Analysis

The immuno and targeted drugs segment is expected to hold the largest share in this market segment

Targeted therapeutics is a type of cancer treatment that uses drugs to precisely 'target' cancer cells without affecting normal cells. Although targeted therapy is an effective treatment, many individuals prefer to use it in combination with other therapies such as traditional or standard chemotherapy, surgery, or radiation therapy. Developments in research for DNA changes and proteins that drive cancer are proving effective to design promising treatments that target such proteins. For different types of cancers come different types of drugs that individually target distinct cancer. However, tumors are tested to check the target, and provide therapy if the drugs are available. As traditional chemotherapy can damage normal cells while killing cancer cells, the targeted therapeutics segment is expected to witness growth during the forecast period. Targeted cancer therapies market is growing due to the increasing incidences of diffuse large b-cell lymphoma (DLBCL). For instance, as per the lymphoma organization, diffuse large b-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the United States, accounting for about 22 percent of newly diagnosed cases of B-cell NHL in the United States. More than 18,000 people are diagnosed with DLBCL each year.

Robust R&D studies are underway for the development of new drugs and therapies for DLBCLs. Several products of different companies are in different phases of clinical trials and will be available in the market during the forecast period. For instance, Roche, Glofitamab (Anti-CD20 CD3 TCB, RG6026) is a T cell-engaging bispecific antibody, designed to engage both CD20 on B cells and CD3 on T cells. By engaging both targets simultaneously, the antibody activates the T cells to attack and eliminate the B cells, allowing treatment of B cell cancers such as non-Hodgkin's lymphoma is under Phase 1 clinical trials is expected to complete by 2022.

Geographical Analysis

North America region holds the largest market share of global diffuse large b-cell lymphoma therapeutics market

North America dominates the market owing to the factor such as increasing prevalence of diffuse large b-cell lymphoma (DLBCL) cases and rising healthcare awareness among the peoples of the region. As per the lymphoma organization, diffuse large b-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the United States, accounting for about 22 percent of newly diagnosed cases of B-cell NHL in the United States. More than 18,000 people are diagnosed with DLBCL each year. The estimates are expected to increase due to the rising trend in the Non-Hodgkin Lymphoma (NHL) incidence as well as DLBCL incidence in the region, combined with underlying demographic changes. It is a mature B-cell neoplasm emanating from the germinal center & post germinal center B-cells.

Furthermore, increasing focus of manufacturers on adoption of inorganic growth strategies such as partnerships and acquisitions, in order to strengthen their product portfolio of relapsed or refractory diffuse large B-cell lymphoma which is anticipated to drive the market growth in the region. For instance, the FDA recently authorized Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL).

Competitive Landscape

The global diffuse large b-cell lymphoma therapeutics market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include F. Hoffmann-La Roche Ltd, Novartis AG, Celltrion, Karyopharm Therapeutics, Kite Pharma, MorphoSys AG, AbbVie, CTI BioPharma, Seagen Inc., TG Therapeutics. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the wound care management devices globally. For instance, On February 19, 2019, The FDA granted Priority Review for polatuzumab vedotin in combination with bendamustine plus Rituxan (rituximab) (BR) for the treatment of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Global Diffuse Large B-cell Lymphoma Therapeutics Market - Key Companies to Watch

F. Hoffmann-La Roche Ltd

Company Overview: Roche was founded in 1896 in Basel, Switzerland. It creates innovative medicines and diagnostic tests that help millions of patients globally. Roche was one of the first companies to bring targeted treatments to patients. With combined strength in pharmaceuticals and diagnostics, they are better equipped than any other company to drive personalized healthcare further. Two-thirds of their research and development projects are being developed with companion diagnostics. Genentech become a member of the Roche Group in March of 2009. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

Product Portfolio: The company portfolio includes Rituxan (rituximab)/MabThera was the first therapeutic monoclonal antibody to target cells that have the CD20 marker on their surface. These cells are central to many blood cancers, including common forms of lymphoma and leukaemia.

Key Developments: In June 2019, the U.S FDA approved Roche's Polivy in combination with bendamustine plus Rituxan (rituximab) (BR) for people with previously treated aggressive lymphoma i.e., diffuse large B-cell lymphoma (DLBCL).

The global diffuse large b-cell lymphoma therapeutics market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Drug Type
  • 3.2. Market Snippet by Route of Administration
  • 3.3. Market Snippet by End-user
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing preference for targeted therapies
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Patent Analysis
  • 5.3. Pipeline Analysis
  • 5.4. Epidemiology
  • 5.5. Supply Chain Analysis
  • 5.6. Pricing Analysis
  • 5.7. Regulatory Analysis
  • 5.8. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 7.1.2. Market Attractiveness Index, By Drug Type
  • 7.2. Immuno and Targeted Drugs*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.2.3. Rituximab (Rituxan)
    • 7.2.4. Polatuzumab vedotin-piiq (Polivy)
    • 7.2.5. Tisagenlecleucel (Kymriah)
    • 7.2.6. Tafasitamab-cxix (Monjuvi)
    • 7.2.7. Selinexor (XPOVIO)
    • 7.2.8. Axicabtagene ciloleucel (Yescarta)
    • 7.2.9. Others (Pembrolizumab (Keytruda), Ibrutinib)
  • 7.3. Others-Combination Drugs

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
    • 8.1.2. Market Attractiveness Index, By Route of Administration Segment
  • 8.2. Intravenous Route*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 8.2.3. Oral

9. By End-user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user Segment
    • 9.1.2. Market Attractiveness Index, By End-user Segment
  • 9.2. Hospitals
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Cancer Centers
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. Key Companies to Watch
  • 11.5. Company with disruptive technology
  • 11.6. Start Up Companies

12. Company Profiles

  • 12.1. F. Hoffmann-La Roche Ltd*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Novartis AG
  • 12.3. Celltrion
  • 12.4. Karyopharm Therapeutics
  • 12.5. Kite Pharma
  • 12.6. MorphoSys AG
  • 12.7. AbbVie
  • 12.8. CTI BioPharma
  • 12.9. Seagen Inc
  • 12.10. TG Therapeutics

LIST NOT EXHAUSTIVE

13. Global Diffuse Large B-cell Lymphoma Therapeutics Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us